Shielding the Heart ❤️🛡️: ARNI's Role in Cardiotoxic Chemotherapy
Dr RR Baliga's "Got Knowledge Doc" Podkast
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
🚀 Breaking News in Cardio-Oncology! 🫀🎗️
A new randomized trial in European Journal of Heart Failure shows that low-dose sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor) given before adjuvant therapy in early breast cancer patients completely prevented cancer therapy-related cardiac dysfunction (CTRCD) over 12 months — 0% vs 26.3% in standard care (p=0.006, NNT=3.8).
💡 Why it matters: CTRCD remains a major risk with anthracyclines and HER2-targeted therapy. Early ARNI initiation, guided by global longitudinal strain (GLS) monitoring, may offer a powerful primary prevention strategy.
📈 Takeaway: This could reshape cardio-oncology practice, but larger Phase III trials are needed to confirm long-term benefits.
#CardioOncology #HeartFailurePrevention #ARNI #BreastCancer #EJHF #CTRCD #GLS #LVEF #PrecisionMedicine #ClinicalTrials